<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02304926</url>
  </required_header>
  <id_info>
    <org_study_id>SIM-EZE-2009-01</org_study_id>
    <nct_id>NCT02304926</nct_id>
  </id_info>
  <brief_title>Effects of Simvastatin and Ezetimibe on Cardiovascular Risk Markers in Patients With Dyslipidemia</brief_title>
  <official_title>Study of Lipoprotein Subfractions, Inflammation, Oxidative Stress and Endothelial Function After Treatment With Simvastatin and Ezetimibe Administered Alone and in Combination in Hyperlipidemic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coadministration of drugs is common in the pharmacologic treatment of dyslipidemia, with
      statins and ezetimibe generally constituting the medication of choice. By acting at different
      levels, the combination of these drugs allows the therapeutic objective to be achieved.
      However, it is not known how these drugs qualitatively affect the composition of lipoprotein
      subfractions, which differ in size and atherogenic potential. The investigators set out to
      evaluate this effect as well as their effects on inflammatory, oxidative stress and
      endothelial function parameters.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consisted of a randomised parallel trial and took place during a period of 2
      months. A total of 42 hyperlipidemic patients were randomly assigned to one of 2 groups: one
      received simvastatin (40 mg/day) and the other received ezetimibe (10 mg/day) for 4 weeks,
      after which both groups were administered combined therapy for an additional 4-week period.
      Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and
      endothelial function parameters were evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Cholesterol Before and After Simvastatin/Ezetimibe Administration</measure>
    <time_frame>Baseline, 4 weeks and 8 weeks</time_frame>
    <description>Total cholesterol concentration was measured by enzymatic assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Low-density Lipoprotein Cholesterol (LDLc) Before and After Simvastatin/Ezetimibe Administration</measure>
    <time_frame>Baseline, 4 weeks and 8 weeks</time_frame>
    <description>Low-density lipoprotein cholesterol (LDLc) concentration was calculated using the method of Friedewald.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>High-density Lipoprotein Cholesterol (HDLc) Before and After Simvastatin/Ezetimibe Administration</measure>
    <time_frame>Baseline, 4 weeks and 8 weeks</time_frame>
    <description>High-density lipoprotein cholesterol (HDLc) concentration was measured using a direct method</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Triglycerides Before and After Simvastatin/Ezetimibe Administration</measure>
    <time_frame>Baseline, 4 weeks and 8 weeks</time_frame>
    <description>Triglyceride concentration were measured by enzymatic assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-HDL Cholesterol Before and After Simvastatin/Ezetimibe Administration</measure>
    <time_frame>Baseline, 4 weeks and 8 weeks</time_frame>
    <description>Non-HDLc concentration was obtained by calculating the difference between total cholesterol and HDLc</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Low Density Lipoprotein Size Before and After Simvastatin/Ezetimibe Administration</measure>
    <time_frame>Baseline, 4 weeks and 8 weeks</time_frame>
    <description>LDL subfractions were separated by high-resolution polyacrylamide gel tubes using the Lipoprint® system. The LDL electrophoretic profile allows 2 patterns to be defined: pattern A or large and buoyant LDL, and pattern non-A or small and dense LDL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apolipoprotein B Before and After Simvastatin/Ezetimibe Administration</measure>
    <time_frame>Baseline, 4 weeks and 8 weeks</time_frame>
    <description>Levels of apolipoprotein B were determined by inmunonephelometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Levels of High-sensitive C-reactive Protein (hsCRP) Before and After Simvastatin/Ezetimibe Administration</measure>
    <time_frame>Baseline, 4 weeks and 8 weeks</time_frame>
    <description>Levels of high-sensitive C-reactive protein (hsCRP) were analysed by a latex-enhanced inmunonephelometric assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of Interleukin-6 (IL-6) Before and After Simvastatin/Ezetimibe Administration</measure>
    <time_frame>Baseline, 4 weeks and 8 weeks</time_frame>
    <description>Levels of proinflammatory cytokines (interleukin-6 (IL-6)) were analysed with a Luminex® 200™ system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of Tumor Necrosis Factor α (TNF-α) Before and After Simvastatin/Ezetimibe Administration</measure>
    <time_frame>Baseline, 4 weeks and 8 weeks</time_frame>
    <description>Levels of proinflammatory cytokines (tumor necrosis factor α (TNF-α)) were analysed with a Luminex® 200™ system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitochondrial Oxygen (O2) Consumption Before and After Simvastatin/Ezetimibe Administration</measure>
    <time_frame>Baseline, 4 weeks and 8 weeks</time_frame>
    <description>Oxidative stress markers (mitochondrial oxygen (O2) consumption) was measured at baseline and after treatment by Clark electrode</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reactive Oxygen Species (ROS) Production Before and After Simvastatin/Ezetimibe Administration</measure>
    <time_frame>Baseline, 4 weeks and 8 weeks</time_frame>
    <description>Oxidative stress markers (Reactive oxygen species (ROS) production) was measured at baseline and after treatment by fluorometric techniques</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Membrane Potential Before and After Simvastatin/Ezetimibe Administration</measure>
    <time_frame>Baseline, 4 weeks and 8 weeks</time_frame>
    <description>Oxidative stress markers (membrane potential) was measured at baseline and after treatment by fluorometric techniques</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of Glutathione (GSH) Before and After Simvastatin/Ezetimibe Administration</measure>
    <time_frame>Baseline, 4 weeks and 8 weeks</time_frame>
    <description>Oxidative stress markers (levels of glutathione (GSH)) was measured at baseline and after treatment by fluorometric techniques</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukocyte Rolling Flux Before and After Simvastatin/Ezetimibe Administration</measure>
    <time_frame>Baseline, 4 weeks and 8 weeks</time_frame>
    <description>Interactions between leukocytes and human umbilical vein endothelial cells were evaluated by flow chamber microscopy. Leukocyte rolling was estimated as the number of leukocytes rolling over 100 μm2 of the endothelial monolayer during a 1-min period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukocyte Adhesion Before and After Simvastatin/Ezetimibe Administration</measure>
    <time_frame>Baseline, 4 weeks and 8 weeks</time_frame>
    <description>Interactions between leukocytes and human umbilical vein endothelial cells were evaluated by flow chamber microscopy. Adhesion was evaluated by counting the number of polymorphonuclear cells that maintained stable contact with human umbilical vein endothelial cells (HUVEC) for 30 seconds.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukocyte Rolling Velocity Before and After Simvastatin/Ezetimibe Administration</measure>
    <time_frame>Baseline, 4 weeks and 8 weeks</time_frame>
    <description>Interactions between leukocytes and human umbilical vein endothelial cells were evaluated by flow chamber microscopy.The rolling velocity in the field of focus was determined by measuring the time required by 20 consecutive leukocytes to cover a distance of 100 μm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of Vascular Cell Adhesion Molecule 1 (VCAM-1) Before and After Simvastatin/Ezetimibe Administration</measure>
    <time_frame>Baseline, 4 weeks and 8 weeks</time_frame>
    <description>The vascular cell adhesion molecule 1 (VCAM-1) was evaluated in serum by Luminex® 200™ system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of Intercellular Adhesion Molecule 1 (ICAM-1) Before and After Simvastatin/Ezetimibe Administration</measure>
    <time_frame>Baseline, 4 weeks and 8 weeks</time_frame>
    <description>The intercellular adhesion molecule 1 (ICAM-1) was evaluated in serum by Luminex® 200™ system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of E-selectin Before and After Simvastatin/Ezetimibe Administration</measure>
    <time_frame>Baseline, 4 weeks and 8 weeks</time_frame>
    <description>E-selectin was evaluated in serum by Luminex® 200™ system</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Simvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyperlipidemic patients received simvastatin (40 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ezetimibe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyperlipidemic patients received ezetimibe (10 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>simvastatin (40 mg/day) for 4 weeks</description>
    <arm_group_label>Simvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe</intervention_name>
    <description>ezetimibe (10 mg/day) for 4 weeks</description>
    <arm_group_label>Ezetimibe</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin + Ezetimibe</intervention_name>
    <description>combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period</description>
    <arm_group_label>Simvastatin</arm_group_label>
    <arm_group_label>Ezetimibe</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  LDL cholesterol concentration of between 160-190 mg/dl in patients with less than 2
             cardiovascular risk factors

          -  LDL concentration of between 130-160 mg/dl in patients that presented 2 or more
             cardiovascular risk factors.

        Cardiovascular risk factors were defined as: age (≥ 45 years in men and ≥55 years in
        women), a smoking habit, hypertension (≥140/90 mmHg), diabetes mellitus, a high-density
        lipoprotein (HDL) cholesterol concentration of ≤ 40mg/dl, and a family history of
        cardiovascular disease.

        Exclusion Criteria:

          -  Triglyceride concentration &gt; 400 mg/dl

          -  Diabetes Mellitus

          -  Kidney, liver, or thyroid disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Hernández, MD, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>FISABIO - University Hospital Dr Peset</affiliation>
  </overall_official>
  <reference>
    <citation>Berneis K, Rizzo M, Berthold HK, Spinas GA, Krone W, Gouni-Berthold I. Ezetimibe alone or in combination with simvastatin increases small dense low-density lipoproteins in healthy men: a randomized trial. Eur Heart J. 2010 Jul;31(13):1633-9. doi: 10.1093/eurheartj/ehq181. Epub 2010 Jun 6.</citation>
    <PMID>20525999</PMID>
  </reference>
  <reference>
    <citation>Florentin M, Liberopoulos EN, Moutzouri E, Rizos CV, Tselepis AD, Elisaf MS. The effect of simvastatin alone versus simvastatin plus ezetimibe on the concentration of small dense low-density lipoprotein cholesterol in subjects with primary hypercholesterolemia. Curr Med Res Opin. 2011 Mar;27(3):685-92. doi: 10.1185/03007995.2010.546394. Epub 2011 Jan 27.</citation>
    <PMID>21271793</PMID>
  </reference>
  <reference>
    <citation>Bays HE, Ose L, Fraser N, Tribble DL, Quinto K, Reyes R, Johnson-Levonas AO, Sapre A, Donahue SR; Ezetimibe Study Group. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther. 2004 Nov;26(11):1758-73.</citation>
    <PMID>15639688</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2014</study_first_submitted>
  <study_first_submitted_qc>November 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2014</study_first_posted>
  <results_first_submitted>April 1, 2015</results_first_submitted>
  <results_first_submitted_qc>May 5, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 21, 2015</results_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana</investigator_affiliation>
    <investigator_full_name>Antonio Hernandez Mijares</investigator_full_name>
    <investigator_title>MD, Phd</investigator_title>
  </responsible_party>
  <keyword>Dyslipidemia</keyword>
  <keyword>Simvastatin</keyword>
  <keyword>Ezetimibe</keyword>
  <keyword>Lipid profile</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Oxidative stress</keyword>
  <keyword>Endothelial function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
    <mesh_term>Ezetimibe, Simvastatin Drug Combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Simvastatin</title>
          <description>20 hyperlipidemic patients received simvastatin (40 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
Simvastatin: simvastatin (40 mg/day) for 4 weeks
Simvastatin + Ezetimibe: combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period</description>
        </group>
        <group group_id="P2">
          <title>Ezetimibe</title>
          <description>20 hyperlipidemic patients received ezetimibe (10 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
Ezetimibe: ezetimibe (10 mg/day) for 4 weeks
Simvastatin + Ezetimibe: combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Simvastatin</title>
          <description>20 hyperlipidemic patients received simvastatin (40 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
Simvastatin: simvastatin (40 mg/day) for 4 weeks
Simvastatin + Ezetimibe: combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period</description>
        </group>
        <group group_id="B2">
          <title>Ezetimibe</title>
          <description>20 hyperlipidemic patients received ezetimibe (10 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
Ezetimibe: ezetimibe (10 mg/day) for 4 weeks
Simvastatin + Ezetimibe: combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.7" spread="12.7"/>
                    <measurement group_id="B2" value="57.6" spread="10.2"/>
                    <measurement group_id="B3" value="57.7" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>Kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.6" spread="3.9"/>
                    <measurement group_id="B2" value="31.2" spread="7.3"/>
                    <measurement group_id="B3" value="29.8" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic blood pressure</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="133" spread="17"/>
                    <measurement group_id="B2" value="137" spread="14"/>
                    <measurement group_id="B3" value="134" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic blood pressure (mm Hg)</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79" spread="10"/>
                    <measurement group_id="B2" value="80" spread="7"/>
                    <measurement group_id="B3" value="80" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Cholesterol Before and After Simvastatin/Ezetimibe Administration</title>
        <description>Total cholesterol concentration was measured by enzymatic assay</description>
        <time_frame>Baseline, 4 weeks and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin</title>
            <description>Hyperlipidemic patients received simvastatin (40 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
Simvastatin: simvastatin (40 mg/day) for 4 weeks
Simvastatin + Ezetimibe: combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe</title>
            <description>Hyperlipidemic patients received ezetimibe (10 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
Ezetimibe: ezetimibe (10 mg/day) for 4 weeks
Simvastatin + Ezetimibe: combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period</description>
          </group>
        </group_list>
        <measure>
          <title>Total Cholesterol Before and After Simvastatin/Ezetimibe Administration</title>
          <description>Total cholesterol concentration was measured by enzymatic assay</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="255" spread="34"/>
                    <measurement group_id="O2" value="253" spread="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180" spread="29"/>
                    <measurement group_id="O2" value="215" spread="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="173" spread="38"/>
                    <measurement group_id="O2" value="169" spread="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Low-density Lipoprotein Cholesterol (LDLc) Before and After Simvastatin/Ezetimibe Administration</title>
        <description>Low-density lipoprotein cholesterol (LDLc) concentration was calculated using the method of Friedewald.</description>
        <time_frame>Baseline, 4 weeks and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin</title>
            <description>Hyperlipidemic patients received simvastatin (40 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
Simvastatin: simvastatin (40 mg/day) for 4 weeks
Simvastatin + Ezetimibe: combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe</title>
            <description>Hyperlipidemic patients received ezetimibe (10 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
Ezetimibe: ezetimibe (10 mg/day) for 4 weeks
Simvastatin + Ezetimibe: combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period</description>
          </group>
        </group_list>
        <measure>
          <title>Low-density Lipoprotein Cholesterol (LDLc) Before and After Simvastatin/Ezetimibe Administration</title>
          <description>Low-density lipoprotein cholesterol (LDLc) concentration was calculated using the method of Friedewald.</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178" spread="26"/>
                    <measurement group_id="O2" value="172" spread="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106" spread="18"/>
                    <measurement group_id="O2" value="138" spread="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" spread="28"/>
                    <measurement group_id="O2" value="94" spread="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Levels of High-sensitive C-reactive Protein (hsCRP) Before and After Simvastatin/Ezetimibe Administration</title>
        <description>Levels of high-sensitive C-reactive protein (hsCRP) were analysed by a latex-enhanced inmunonephelometric assay</description>
        <time_frame>Baseline, 4 weeks and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin</title>
            <description>Hyperlipidemic patients received simvastatin (40 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
Simvastatin: simvastatin (40 mg/day) for 4 weeks
Simvastatin + Ezetimibe: combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe</title>
            <description>Hyperlipidemic patients received ezetimibe (10 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
Ezetimibe: ezetimibe (10 mg/day) for 4 weeks
Simvastatin + Ezetimibe: combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period</description>
          </group>
        </group_list>
        <measure>
          <title>Levels of High-sensitive C-reactive Protein (hsCRP) Before and After Simvastatin/Ezetimibe Administration</title>
          <description>Levels of high-sensitive C-reactive protein (hsCRP) were analysed by a latex-enhanced inmunonephelometric assay</description>
          <units>mg/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.02" spread="3.49"/>
                    <measurement group_id="O2" value="4.43" spread="4.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.82" spread="2.69"/>
                    <measurement group_id="O2" value="3.98" spread="3.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.64" spread="2.21"/>
                    <measurement group_id="O2" value="3.31" spread="3.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Levels of Interleukin-6 (IL-6) Before and After Simvastatin/Ezetimibe Administration</title>
        <description>Levels of proinflammatory cytokines (interleukin-6 (IL-6)) were analysed with a Luminex® 200™ system</description>
        <time_frame>Baseline, 4 weeks and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin</title>
            <description>Hyperlipidemic patients received simvastatin (40 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
Simvastatin: simvastatin (40 mg/day) for 4 weeks
Simvastatin + Ezetimibe: combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe</title>
            <description>Hyperlipidemic patients received ezetimibe (10 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
Ezetimibe: ezetimibe (10 mg/day) for 4 weeks
Simvastatin + Ezetimibe: combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period</description>
          </group>
        </group_list>
        <measure>
          <title>Levels of Interleukin-6 (IL-6) Before and After Simvastatin/Ezetimibe Administration</title>
          <description>Levels of proinflammatory cytokines (interleukin-6 (IL-6)) were analysed with a Luminex® 200™ system</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.44" spread="1.62"/>
                    <measurement group_id="O2" value="2.94" spread="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.83" spread="1.66"/>
                    <measurement group_id="O2" value="3.93" spread="2.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.43" spread="4.30"/>
                    <measurement group_id="O2" value="5.78" spread="3.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Levels of Tumor Necrosis Factor α (TNF-α) Before and After Simvastatin/Ezetimibe Administration</title>
        <description>Levels of proinflammatory cytokines (tumor necrosis factor α (TNF-α)) were analysed with a Luminex® 200™ system</description>
        <time_frame>Baseline, 4 weeks and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin</title>
            <description>Hyperlipidemic patients received simvastatin (40 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
Simvastatin: simvastatin (40 mg/day) for 4 weeks
Simvastatin + Ezetimibe: combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe</title>
            <description>Hyperlipidemic patients received ezetimibe (10 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
Ezetimibe: ezetimibe (10 mg/day) for 4 weeks
Simvastatin + Ezetimibe: combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period</description>
          </group>
        </group_list>
        <measure>
          <title>Levels of Tumor Necrosis Factor α (TNF-α) Before and After Simvastatin/Ezetimibe Administration</title>
          <description>Levels of proinflammatory cytokines (tumor necrosis factor α (TNF-α)) were analysed with a Luminex® 200™ system</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.43" spread="1.87"/>
                    <measurement group_id="O2" value="3.01" spread="2.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.99" spread="1.77"/>
                    <measurement group_id="O2" value="5.09" spread="5.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.43" spread="4.30"/>
                    <measurement group_id="O2" value="4.35" spread="4.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>High-density Lipoprotein Cholesterol (HDLc) Before and After Simvastatin/Ezetimibe Administration</title>
        <description>High-density lipoprotein cholesterol (HDLc) concentration was measured using a direct method</description>
        <time_frame>Baseline, 4 weeks and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin</title>
            <description>Hyperlipidemic patients received simvastatin (40 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
Simvastatin: simvastatin (40 mg/day) for 4 weeks
Simvastatin + Ezetimibe: combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe</title>
            <description>Hyperlipidemic patients received ezetimibe (10 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
Ezetimibe: ezetimibe (10 mg/day) for 4 weeks
Simvastatin + Ezetimibe: combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period</description>
          </group>
        </group_list>
        <measure>
          <title>High-density Lipoprotein Cholesterol (HDLc) Before and After Simvastatin/Ezetimibe Administration</title>
          <description>High-density lipoprotein cholesterol (HDLc) concentration was measured using a direct method</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47" spread="11"/>
                    <measurement group_id="O2" value="53" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" spread="13"/>
                    <measurement group_id="O2" value="53" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51" spread="13"/>
                    <measurement group_id="O2" value="53" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Triglycerides Before and After Simvastatin/Ezetimibe Administration</title>
        <description>Triglyceride concentration were measured by enzymatic assay</description>
        <time_frame>Baseline, 4 weeks and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin</title>
            <description>Hyperlipidemic patients received simvastatin (40 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
Simvastatin: simvastatin (40 mg/day) for 4 weeks
Simvastatin + Ezetimibe: combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe</title>
            <description>Hyperlipidemic patients received ezetimibe (10 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
Ezetimibe: ezetimibe (10 mg/day) for 4 weeks
Simvastatin + Ezetimibe: combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period</description>
          </group>
        </group_list>
        <measure>
          <title>Triglycerides Before and After Simvastatin/Ezetimibe Administration</title>
          <description>Triglyceride concentration were measured by enzymatic assay</description>
          <units>mg/dl</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141" lower_limit="104" upper_limit="168"/>
                    <measurement group_id="O2" value="120" lower_limit="81" upper_limit="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117" lower_limit="82" upper_limit="136"/>
                    <measurement group_id="O2" value="105" lower_limit="81" upper_limit="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104" lower_limit="82" upper_limit="146"/>
                    <measurement group_id="O2" value="81" lower_limit="61" upper_limit="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mitochondrial Oxygen (O2) Consumption Before and After Simvastatin/Ezetimibe Administration</title>
        <description>Oxidative stress markers (mitochondrial oxygen (O2) consumption) was measured at baseline and after treatment by Clark electrode</description>
        <time_frame>Baseline, 4 weeks and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin</title>
            <description>Hyperlipidemic patients received simvastatin (40 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
Simvastatin: simvastatin (40 mg/day) for 4 weeks
Simvastatin + Ezetimibe: combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe</title>
            <description>Hyperlipidemic patients received ezetimibe (10 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
Ezetimibe: ezetimibe (10 mg/day) for 4 weeks
Simvastatin + Ezetimibe: combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period</description>
          </group>
        </group_list>
        <measure>
          <title>Mitochondrial Oxygen (O2) Consumption Before and After Simvastatin/Ezetimibe Administration</title>
          <description>Oxidative stress markers (mitochondrial oxygen (O2) consumption) was measured at baseline and after treatment by Clark electrode</description>
          <units>Nmol O2/min/million cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" spread="0.15"/>
                    <measurement group_id="O2" value="1.09" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.54" spread="0.12"/>
                    <measurement group_id="O2" value="1.31" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.76" spread="0.21"/>
                    <measurement group_id="O2" value="1.67" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reactive Oxygen Species (ROS) Production Before and After Simvastatin/Ezetimibe Administration</title>
        <description>Oxidative stress markers (Reactive oxygen species (ROS) production) was measured at baseline and after treatment by fluorometric techniques</description>
        <time_frame>Baseline, 4 weeks and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin</title>
            <description>Hyperlipidemic patients received simvastatin (40 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
Simvastatin: simvastatin (40 mg/day) for 4 weeks
Simvastatin + Ezetimibe: combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe</title>
            <description>Hyperlipidemic patients received ezetimibe (10 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
Ezetimibe: ezetimibe (10 mg/day) for 4 weeks
Simvastatin + Ezetimibe: combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period</description>
          </group>
        </group_list>
        <measure>
          <title>Reactive Oxygen Species (ROS) Production Before and After Simvastatin/Ezetimibe Administration</title>
          <description>Oxidative stress markers (Reactive oxygen species (ROS) production) was measured at baseline and after treatment by fluorometric techniques</description>
          <units>Fluorescence Units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.7" spread="8.1"/>
                    <measurement group_id="O2" value="72.8" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.2" spread="8.9"/>
                    <measurement group_id="O2" value="63.5" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.3" spread="7.9"/>
                    <measurement group_id="O2" value="48.9" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Membrane Potential Before and After Simvastatin/Ezetimibe Administration</title>
        <description>Oxidative stress markers (membrane potential) was measured at baseline and after treatment by fluorometric techniques</description>
        <time_frame>Baseline, 4 weeks and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin</title>
            <description>Hyperlipidemic patients received simvastatin (40 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
Simvastatin: simvastatin (40 mg/day) for 4 weeks
Simvastatin + Ezetimibe: combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe</title>
            <description>Hyperlipidemic patients received ezetimibe (10 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
Ezetimibe: ezetimibe (10 mg/day) for 4 weeks
Simvastatin + Ezetimibe: combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period</description>
          </group>
        </group_list>
        <measure>
          <title>Membrane Potential Before and After Simvastatin/Ezetimibe Administration</title>
          <description>Oxidative stress markers (membrane potential) was measured at baseline and after treatment by fluorometric techniques</description>
          <units>Fluorescence Units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.6" spread="5.8"/>
                    <measurement group_id="O2" value="48.4" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5" spread="5.4"/>
                    <measurement group_id="O2" value="56.7" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.4" spread="8.4"/>
                    <measurement group_id="O2" value="67.5" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Levels of Glutathione (GSH) Before and After Simvastatin/Ezetimibe Administration</title>
        <description>Oxidative stress markers (levels of glutathione (GSH)) was measured at baseline and after treatment by fluorometric techniques</description>
        <time_frame>Baseline, 4 weeks and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin</title>
            <description>Hyperlipidemic patients received simvastatin (40 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
Simvastatin: simvastatin (40 mg/day) for 4 weeks
Simvastatin + Ezetimibe: combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe</title>
            <description>Hyperlipidemic patients received ezetimibe (10 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
Ezetimibe: ezetimibe (10 mg/day) for 4 weeks
Simvastatin + Ezetimibe: combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period</description>
          </group>
        </group_list>
        <measure>
          <title>Levels of Glutathione (GSH) Before and After Simvastatin/Ezetimibe Administration</title>
          <description>Oxidative stress markers (levels of glutathione (GSH)) was measured at baseline and after treatment by fluorometric techniques</description>
          <units>Fluorescence Units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.68" spread="0.63"/>
                    <measurement group_id="O2" value="2.85" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.67" spread="0.59"/>
                    <measurement group_id="O2" value="3.79" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.92" spread="1.24"/>
                    <measurement group_id="O2" value="7.51" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Leukocyte Rolling Flux Before and After Simvastatin/Ezetimibe Administration</title>
        <description>Interactions between leukocytes and human umbilical vein endothelial cells were evaluated by flow chamber microscopy. Leukocyte rolling was estimated as the number of leukocytes rolling over 100 μm2 of the endothelial monolayer during a 1-min period.</description>
        <time_frame>Baseline, 4 weeks and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin</title>
            <description>Hyperlipidemic patients received simvastatin (40 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
Simvastatin: simvastatin (40 mg/day) for 4 weeks
Simvastatin + Ezetimibe: combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe</title>
            <description>Hyperlipidemic patients received ezetimibe (10 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
Ezetimibe: ezetimibe (10 mg/day) for 4 weeks
Simvastatin + Ezetimibe: combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period</description>
          </group>
        </group_list>
        <measure>
          <title>Leukocyte Rolling Flux Before and After Simvastatin/Ezetimibe Administration</title>
          <description>Interactions between leukocytes and human umbilical vein endothelial cells were evaluated by flow chamber microscopy. Leukocyte rolling was estimated as the number of leukocytes rolling over 100 μm2 of the endothelial monolayer during a 1-min period.</description>
          <units>polymorphonuclear cells/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="412" spread="132"/>
                    <measurement group_id="O2" value="421" spread="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="225" spread="61"/>
                    <measurement group_id="O2" value="392" spread="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147" spread="51"/>
                    <measurement group_id="O2" value="196" spread="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Non-HDL Cholesterol Before and After Simvastatin/Ezetimibe Administration</title>
        <description>Non-HDLc concentration was obtained by calculating the difference between total cholesterol and HDLc</description>
        <time_frame>Baseline, 4 weeks and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin</title>
            <description>Hyperlipidemic patients received simvastatin (40 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
Simvastatin: simvastatin (40 mg/day) for 4 weeks
Simvastatin + Ezetimibe: combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe</title>
            <description>Hyperlipidemic patients received ezetimibe (10 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
Ezetimibe: ezetimibe (10 mg/day) for 4 weeks
Simvastatin + Ezetimibe: combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period</description>
          </group>
        </group_list>
        <measure>
          <title>Non-HDL Cholesterol Before and After Simvastatin/Ezetimibe Administration</title>
          <description>Non-HDLc concentration was obtained by calculating the difference between total cholesterol and HDLc</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208" spread="29"/>
                    <measurement group_id="O2" value="200" spread="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130" spread="23"/>
                    <measurement group_id="O2" value="162" spread="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122" spread="31"/>
                    <measurement group_id="O2" value="115" spread="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Low Density Lipoprotein Size Before and After Simvastatin/Ezetimibe Administration</title>
        <description>LDL subfractions were separated by high-resolution polyacrylamide gel tubes using the Lipoprint® system. The LDL electrophoretic profile allows 2 patterns to be defined: pattern A or large and buoyant LDL, and pattern non-A or small and dense LDL.</description>
        <time_frame>Baseline, 4 weeks and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin</title>
            <description>20 hyperlipidemic patients received simvastatin (40 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
Simvastatin: simvastatin (40 mg/day) for 4 weeks
Simvastatin + Ezetimibe: combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe</title>
            <description>19 hyperlipidemic patients received ezetimibe (10 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
Ezetimibe: ezetimibe (10 mg/day) for 4 weeks
Simvastatin + Ezetimibe: combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period</description>
          </group>
        </group_list>
        <measure>
          <title>Low Density Lipoprotein Size Before and After Simvastatin/Ezetimibe Administration</title>
          <description>LDL subfractions were separated by high-resolution polyacrylamide gel tubes using the Lipoprint® system. The LDL electrophoretic profile allows 2 patterns to be defined: pattern A or large and buoyant LDL, and pattern non-A or small and dense LDL.</description>
          <units>Angström</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="268.1" spread="4.7"/>
                    <measurement group_id="O2" value="270.4" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="270.4" spread="2.9"/>
                    <measurement group_id="O2" value="271.5" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="271.7" spread="2.7"/>
                    <measurement group_id="O2" value="272.0" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Leukocyte Adhesion Before and After Simvastatin/Ezetimibe Administration</title>
        <description>Interactions between leukocytes and human umbilical vein endothelial cells were evaluated by flow chamber microscopy. Adhesion was evaluated by counting the number of polymorphonuclear cells that maintained stable contact with human umbilical vein endothelial cells (HUVEC) for 30 seconds.</description>
        <time_frame>Baseline, 4 weeks and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin</title>
            <description>Hyperlipidemic patients received simvastatin (40 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
Simvastatin: simvastatin (40 mg/day) for 4 weeks
Simvastatin + Ezetimibe: combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe</title>
            <description>Hyperlipidemic patients received ezetimibe (10 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
Ezetimibe: ezetimibe (10 mg/day) for 4 weeks
Simvastatin + Ezetimibe: combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period</description>
          </group>
        </group_list>
        <measure>
          <title>Leukocyte Adhesion Before and After Simvastatin/Ezetimibe Administration</title>
          <description>Interactions between leukocytes and human umbilical vein endothelial cells were evaluated by flow chamber microscopy. Adhesion was evaluated by counting the number of polymorphonuclear cells that maintained stable contact with human umbilical vein endothelial cells (HUVEC) for 30 seconds.</description>
          <units>polymorphonuclear cells/mm2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.1" spread="8.2"/>
                    <measurement group_id="O2" value="25.6" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" spread="4.1"/>
                    <measurement group_id="O2" value="23.8" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9" spread="2.5"/>
                    <measurement group_id="O2" value="12.5" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Leukocyte Rolling Velocity Before and After Simvastatin/Ezetimibe Administration</title>
        <description>Interactions between leukocytes and human umbilical vein endothelial cells were evaluated by flow chamber microscopy.The rolling velocity in the field of focus was determined by measuring the time required by 20 consecutive leukocytes to cover a distance of 100 μm.</description>
        <time_frame>Baseline, 4 weeks and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin</title>
            <description>Hyperlipidemic patients received simvastatin (40 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
Simvastatin: simvastatin (40 mg/day) for 4 weeks
Simvastatin + Ezetimibe: combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe</title>
            <description>Hyperlipidemic patients received ezetimibe (10 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
Ezetimibe: ezetimibe (10 mg/day) for 4 weeks
Simvastatin + Ezetimibe: combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period</description>
          </group>
        </group_list>
        <measure>
          <title>Leukocyte Rolling Velocity Before and After Simvastatin/Ezetimibe Administration</title>
          <description>Interactions between leukocytes and human umbilical vein endothelial cells were evaluated by flow chamber microscopy.The rolling velocity in the field of focus was determined by measuring the time required by 20 consecutive leukocytes to cover a distance of 100 μm.</description>
          <units>micrometer/second</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="469" spread="53"/>
                    <measurement group_id="O2" value="524" spread="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="553" spread="54"/>
                    <measurement group_id="O2" value="533" spread="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="608" spread="43"/>
                    <measurement group_id="O2" value="629" spread="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apolipoprotein B Before and After Simvastatin/Ezetimibe Administration</title>
        <description>Levels of apolipoprotein B were determined by inmunonephelometry</description>
        <time_frame>Baseline, 4 weeks and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin</title>
            <description>Hyperlipidemic patients received simvastatin (40 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
Simvastatin: simvastatin (40 mg/day) for 4 weeks
Simvastatin + Ezetimibe: combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe</title>
            <description>Hyperlipidemic patients received ezetimibe (10 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
Ezetimibe: ezetimibe (10 mg/day) for 4 weeks
Simvastatin + Ezetimibe: combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period</description>
          </group>
        </group_list>
        <measure>
          <title>Apolipoprotein B Before and After Simvastatin/Ezetimibe Administration</title>
          <description>Levels of apolipoprotein B were determined by inmunonephelometry</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139" spread="20"/>
                    <measurement group_id="O2" value="127" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" spread="18"/>
                    <measurement group_id="O2" value="110" spread="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" spread="18"/>
                    <measurement group_id="O2" value="79" spread="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Levels of Vascular Cell Adhesion Molecule 1 (VCAM-1) Before and After Simvastatin/Ezetimibe Administration</title>
        <description>The vascular cell adhesion molecule 1 (VCAM-1) was evaluated in serum by Luminex® 200™ system</description>
        <time_frame>Baseline, 4 weeks and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin</title>
            <description>Hyperlipidemic patients received simvastatin (40 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
Simvastatin: simvastatin (40 mg/day) for 4 weeks
Simvastatin + Ezetimibe: combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe</title>
            <description>Hyperlipidemic patients received ezetimibe (10 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
Ezetimibe: ezetimibe (10 mg/day) for 4 weeks
Simvastatin + Ezetimibe: combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period</description>
          </group>
        </group_list>
        <measure>
          <title>Levels of Vascular Cell Adhesion Molecule 1 (VCAM-1) Before and After Simvastatin/Ezetimibe Administration</title>
          <description>The vascular cell adhesion molecule 1 (VCAM-1) was evaluated in serum by Luminex® 200™ system</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1314" spread="251"/>
                    <measurement group_id="O2" value="1371" spread="342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1137" spread="407"/>
                    <measurement group_id="O2" value="1166" spread="526"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1074" spread="385"/>
                    <measurement group_id="O2" value="1220" spread="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Levels of Intercellular Adhesion Molecule 1 (ICAM-1) Before and After Simvastatin/Ezetimibe Administration</title>
        <description>The intercellular adhesion molecule 1 (ICAM-1) was evaluated in serum by Luminex® 200™ system</description>
        <time_frame>Baseline, 4 weeks and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin</title>
            <description>Hyperlipidemic patients received simvastatin (40 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
Simvastatin: simvastatin (40 mg/day) for 4 weeks
Simvastatin + Ezetimibe: combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe</title>
            <description>Hyperlipidemic patients received ezetimibe (10 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
Ezetimibe: ezetimibe (10 mg/day) for 4 weeks
Simvastatin + Ezetimibe: combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period</description>
          </group>
        </group_list>
        <measure>
          <title>Levels of Intercellular Adhesion Molecule 1 (ICAM-1) Before and After Simvastatin/Ezetimibe Administration</title>
          <description>The intercellular adhesion molecule 1 (ICAM-1) was evaluated in serum by Luminex® 200™ system</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188" spread="46.5"/>
                    <measurement group_id="O2" value="160.6" spread="37.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.5" spread="53.4"/>
                    <measurement group_id="O2" value="114.7" spread="24.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.2" spread="52.2"/>
                    <measurement group_id="O2" value="108.1" spread="36.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Levels of E-selectin Before and After Simvastatin/Ezetimibe Administration</title>
        <description>E-selectin was evaluated in serum by Luminex® 200™ system</description>
        <time_frame>Baseline, 4 weeks and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Simvastatin</title>
            <description>Hyperlipidemic patients received simvastatin (40 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
Simvastatin: simvastatin (40 mg/day) for 4 weeks
Simvastatin + Ezetimibe: combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe</title>
            <description>Hyperlipidemic patients received ezetimibe (10 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
Ezetimibe: ezetimibe (10 mg/day) for 4 weeks
Simvastatin + Ezetimibe: combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period</description>
          </group>
        </group_list>
        <measure>
          <title>Levels of E-selectin Before and After Simvastatin/Ezetimibe Administration</title>
          <description>E-selectin was evaluated in serum by Luminex® 200™ system</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.1" spread="21.0"/>
                    <measurement group_id="O2" value="39.7" spread="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.9" spread="16.0"/>
                    <measurement group_id="O2" value="30.5" spread="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.2" spread="11.0"/>
                    <measurement group_id="O2" value="24.4" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were not collected</time_frame>
      <desc>Adverse events were not collected</desc>
      <group_list>
        <group group_id="E1">
          <title>Adverse Events Were Not Collected</title>
          <description>Adverse events were not collected</description>
        </group>
        <group group_id="E2">
          <title>Not Available</title>
          <description>Adverse events were not collected</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Antonio Hernández</name_or_title>
      <organization>FISABIO-University Hospital Dr Peset</organization>
      <phone>961622492</phone>
      <email>hernandez_antmij@gva.es</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

